2023 UPDATES IN LIGHT CHAIN (AL) AMYLOIDOSIS

Anita D'Souza MD, MS Associate Professor of Medicine, Medical College of Wisconsin Milwaukee, WI 53226 11th Feb 2023



Disclosures

- Clinical Trial Support: Abbvie, Sanofi, Takeda, Janssen, Novartis, Regeneron, TeneoBio, CAELUM, Prothena
- Ad Board and Consulting fees: BMS, Janssen, Prothena



Objectives

AL amyloidosis staging and response assessment


- Treatment of newly diagnosed and relapsed/refractory AL
- Supportive care



When you see a newly diagnosed AL amyloidosis

- Subtype the amyloid so you know what you are treating. Whenever possible refer to amyloid center
- Know affected organs and numbers to follow
- Treatment of AL amyloidosis
- Supportive care





Plasma cell-directed chemotherapy

clonal free

light chains



No effective treatments Needs time to improve Chemotherapy adverse effects can worsen e.g., fluid retention, cardiotoxicity, neuropathy

organ AL deposition

leading to dysfuntion


misfolded

(AL)

light chains

AL Amyloidosis: Overall Survival by Stage

OS by 2012 Mayo Clinic Stage (n = 758)



OF WISCONSIN

Staging System	Markers/Thresholds	Stages
2004 Mayo Clinic Cardiac Staging System with 2015 European modification	NT-proBNP >332 ng/L cTnT >0.035 ng/mL (or cTnI >0.1 ng/mL)	I. 0 markers above cutoff II. 1 marker above cutoff IIIa. Both markers above cutoff and NT-proBNP <8500 ng/L IIIb. Both markers above cutoff and NT-proBNP ≥8500 ng/L
2012 Revised Mayo Clinic Staging System	NT-proBNP >1800 ng/L cTnT >0.025 ng/mL dFLC >180 mg/L	I. 0 markers above cutoff II. 1 marker above cutoff III. 2 markers above cutoff IV. 3 markers above cutoff
2014 Palladini Renal Staging System eGFR <50 mL/min per 1.73 m ² proteinuria >5 g per 24 hr		 I. Both eGFR above and proteinuria below cutoffs II. Either eGFR below or proteinuria above cutoffs III. Both eGFR below and proteinuria above cutoffs

Kumar et al. JCO. 2012;30:989. Milani et al. Mediterr J Hematol Infect Dis. 2018;10:e2018022.

AL Amyloidosis Goals for Therapy and Measuring Response

Goals for Therapy

- Deep response: normalization or near normalization of serum free light chain
- Durable response
- Minimizing toxicity: risk-adapted therapy that does not lead to mortality or decompensate patients
- Supportive care

Measuring Response in AL Amyloidosis

- Hematologic response
 - Reduction in M protein (SPEP, UPEP, dFLC)
- Organ response
 - Cardiac: NT-ProBNP
 - Renal: 24-hr urine protein, eGFR
 - Liver: liver span, alkaline phosphatase
- Imaging
 - Echo: Global longitudinal strain
 - CMR: Myocardial ECV tracking, T1 mapping, LGE
- Functional outcomes
 - Six-minute walk test
 - NYHA Class
 - PROs/HRQL: KCCQ, SF-36, and PROMIS



Palladini et al. JCO. 2012;30:4541. Fotiou et al. Hemasphere. 2020;4:e454. Mutchar et al. Leukemia. 2018;32:2240.

Hematologic Response Criteria

Response	Definition		
	 Both criteria must be met Absence of amyloidogenic light chains (either free and/or as part of a complete immunoglobulin) defined by negative IFE of both serum and urine		
Complete response			
Very good partial response	dFLC concentration <40 mg/L or 4 mg/dl		
Partial response	dFLC decrease >50% compared with baseline		
No response	All other patients		
MEDICAL COLLEGE OF WISCONSIN	Palladini et al. Amyloid. 2021;28:1.		
DF WISCONSIN	Palladini et al. Amyloid. 2021;28:1.		

Organ Response Criteria in AL Amyloidosis

Organ	Response	Progression
Heart	NT-proBNP response: >30% and ↓ >300 ng/L in patients w/baseline NT-proBNP ≥650 ng/L or NYHA class response: ↓ ≥2 class in patients w/baseline NYHA class 3-4	NT-proBNP progression: >30% and ↑ >300 ng/L or cTn progression: ↑ ≥33% or Ejection fraction progression: ↓ ≥10%
Kidney	↓ 50% (≥0.5 g/d) of 24-hr urine protein (required: >0.5 g/d pretreatment); creatinine and creatinine clearance must not worsen by 25% above BL	50% ↑ (≥1 g/d) of 24-hr urine protein to >1 g/d or 25% worsening of creatinine or creatinine clearance
Liver	50%↓ in abnormal AP and↓≥2 cm in liver size (radiographic)	50% ↑ of AP above lowest value



Comenzo et al. Leukemia. 2012;26:2317.


Conversion/Cross-Reference by Biomarkers

	cTnT, µg/L	cTnl, µg/L	Hs-cTnT, ng/L	NT-proBNP, ng/L	BNP, ng/L
2004 Mayo Stage	≥0.035	≥0.1	≥50	≥332	81
2015 European modification of Mayo 2004	≥0.035	≥0.1	≥50	≥332 >8,500	81 >700
2012 Mayo Stage	≥0.025	ND	>40	≥1800	≥400



Muchtar et al. Blood. 2019;133:763.

ANDROMEDA: VCD vs Daratumumab/VCD for AL






Patients enrolled at 109 sites in 22 countries from May 2018 through August 2019


1. Palladini et al. Blood. 2020;136:71. 2. Kastritis et al. NEJM. 2021;385:46.



ANDROMEDA: Endpoints and Results



ANDROMEDA: Key Organ Status at 6 months



Cardiac and renal response rates doubled



Organ progression reduced by approximately two thirds


What we learned and what we didn't

• What we learned

- Adding daratumumab to CyBorD improved complete HR rate and doubled cardiac and renal response at 6 months
- Daratumumab does not improve early (cardiac) mortality
- What we did not learn
 - Is there any role for ASCT consolidation in transplant-eligible patients?
 - Is daratumumab maintenance needed for those in cHR?
 - Will long-term survival be improved with addition of daratumumab?
 - Can daratumumab be safely used in patients with advanced cardiac stage?



Monoclonal antibodies in AL Amyloidosis



Birtamimab and CAEL 101 phase 3 trials- similarities and differences

	Birtamimab (NEOD001)	Anselamimab (CAEL-101)
Dosing	Every 4 weeks, 1-hour infusion	Weekly for 4 weeks, then bi-weekly, 2-hour infusion
Ongoing Trials	 AFFIRM-AL Newly diagnosed, treatment naïve Mayo Stage IV patients with cardiac involvement 	 CAEL-101 301 and 302 studies Newly diagnosed, treatment naïve Mayo Stage IIIA & IIIb patients with cardiac involvement
Endpoints	 Primary Endpoint: All-cause mortality Secondary Endpoints: SF-36v2 PCS, 6MWT Exploratory Endpoints: GLS, hospitalizations 	 Primary Endpoint: All-cause mortality Secondary Endpoints: 6MWT, KCCQ-OS, SF-36v2 PCS, GLS
Key criteria	 2:1 randomization Mayo 2012 stage 4, excludes IIIb stage NT-proBNP 1800-8500/BNP 400, cTNT 0.025/hsTNT 40, dFLC 180 Allows daratumumab-based treatment, no intent for ASCT No prior chemotherapy 	 2:1 randomization Mayo 2004 stage III with European modification NT-proBNP >=650, cTNT 0.035/hsTNT 50/cTnI 0.1, measurable hematologic disease Allows daratumumab-based treatment, no intent for ASCT Up to 2 weeks of chemotherapy prior to randomization



Clinicaltrials.gov


When to move to Second-line Therapy?

- 1. Issues with toxicity that cannot be corrected by dose modifications or supportive care
- 2. Refractory or inadequate response
- 3. Relapsing or progressive disease





What is an Inadequate Hematologic Response?





Ravichandran et al. Br J Haematol. 2022;198:328.

Newly diagnosed AL amyloidosis with <VGPR at 1 mo 2 risk factors predicted for lack of deepening response by 6 months

- Baseline dFLC >400 mg/L
- < PR at 1 month
- **Recommendation:** At 1 month, change therapy for patients with **both** risk factors (<PR and baseline dFLC > 400 mg/L
- At 3 mo, among intermediate- and low-risk patients:
 - Only 23% of patients with < VGPR at 3 mo had an improved response at 6 mo
- **Recommendation:** At 3 months, change therapy in patients not achieving VGPR

Definition of Hematologic Relapse/Progression

2005 ISA Criteria ¹	Pavia Criteria for High-Risk dFLC Progression ²
From CR	Requires all 3
 Any detectable monoclonal protein <i>or</i> Abnormal FLC ratio (& doubled light chain) 	 dFLC >20 mg/L (absolute value)
	 dFLC >20% of baseline (diagnostic)
	■ dFLC ↑ >50% above nadir of best response
From PR	
■ iFLC ↑ 50% (absolute value >100 mg/L) or	
Serum M protein ↑ 50% to 0.5 g/dL, or	
24-hr urine M protein ↑ 50% to >0.2 g/day	



OF WISCONSIN

FDICAL

1. Gertz et al. Am J Hematol. 2005;79:319. 2. Palladini et al. Blood. 2018;131:525.

AL Amyloidosis Therapies: Off-Target Toxicities


- Melphalan
 - High dose for ASCT
 - Low dose oral

Cardiotoxic 岸

- Cyclophosphamide
- Bendamustine
- Bortezomib
- Ixazomib

FDICAL

Carfilzomib






 Dexamethasone R Pomalidomide 🐺 🎍 🏜 🐲 Lenalidomide è è Thalidomide Daratumumab* X Venetoclax Belantamab[†] Myopathic Edema Myelotoxic Ocular toxic

*Also, isatuximab ⁺Belantamab was pulled from US market in November 2022

Neurotoxic



Venetoclax for AL Amyloidosis with t(11;14)



Slide credit: clinica

Hematology-Specific Supportive Care

Medications

- Antivirals (acyclovir)
- Antinausea
- Acid blockers
- Sleep aids
- Diuretics
- Laxatives

Counteract

- Risk of shingles
- Bortezomib, cyclophosphamide
- Dexamethasone
- Dexamethasone
- Dexamethasone
- Bortezomib



Supportive Care for Organ Amyloidosis

CARDIAC AND RENAL

✓ Diuretics

Loop

Spironolactone

Albumin diuresis

- ✓ Daily weight & BP
- ✓ Sodium restriction
- ✓ Compression stockings
- ✓ Avoid nephrotoxic drugs (NSAIDs)
- ✓ Avoid typical heart failure drugs e.g., beta-blockers, Calcium channel blockers
- \checkmark Atrial fibrillation- amiodarone or digoxin

Anticoagulation as appropriate

NEUROLOGIC

Peripheral neuropathy

- Medications- gabapentin, pregabalin, duloxetine, nortriptyline, amitriptyline, topicals- lidocaine, ketamine
- ✓ Scrambler therapy
- ✓ Acupuncture
- ✓ Gait aids, PT/OT
- Autonomic neuropathy- LOW BP
- ✓ Compression stockings
- ✓ Raise bed head
- ✓ Avoid standing too quickly
- Exercise (avoid heat, hot tubs)
- ✓ Medications- midodrine, droxidopa, pyridostigmine
- \checkmark If no cardiac/renal restriction- salt tablets, fludrocortisone



Take home points

- Heterogeneous disease with protean manifestations
 - Appropriate staging and measuring response to treatments using biomarkers
- Early treatment goals- rapid and deep hematologic response, fibril-directed agents on clinical trials
 - DaraVCD is the only FDA approved treatment and SOC for newly diagnosed AL
 - Role of daraVCD in advanced cardiac stage
 - Role of ASCT in newly diagnosed AL
- Multiple hematologic treatments are available for relapsed AL amyloidosis
 - When to start treatment
 - Unique toxicities of various treatments
- Supportive care is essential in the management of AL amyloidosis



Treating the underlying disease (e.g., chemotherapy) is only half the job

Acknowledgments

MCW Plasma Cell Disorders Team, Cancer Center

A D'Souza, MD	C Skoog, PA-C	K Johnson, RN
B Dhakal, MD	A Goff, APNP	J Esselmann, RN
M Mohan, MD	J Kujawa, RN	Plasma Cell DOT, CTO
R Narra, MD	J Loyda, RN	
M Pasquini, MD	K Wojniack, RN	

Multidisciplinary Amyloidosis Specialists:

Cardiology: C Mueller, MD, E Raichlin, MD Cardiac Imaging: J Rubenstein, MD Electrophysiology: M Berger, MD, J Rubenstein, MD Neurology: M Collins, MD, J Figueroa, MD, N Adaguntla, MD

Contact:

Email: <u>andsouza@mcw.edu</u> Cell: 262-501-5944







Available Clinical Trials at Froedtert & MCW CC

Newly diagnosed AL -CAEL-101 301 and 302 -NEOD001 Relapsed AL -DaraPomDex -STI-6129 -Venetoclax Imaging -Florbetapir scan

> Funding Support: NHLBI K23 HL141445 NHLBI R01 HL166339 Advancing a Healthier Wisconsin CTSI of SE Wisconsin MCW & Froedtert Cancer Center